Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
Holding NBIX?
Track your performance easily
NBIX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$103.63 - $157.98
Previous Close$119.85
Volume1.05M
Average Volume (3M)925.19K
Market Cap
$12.10B
Enterprise Value$11.32B
Total Cash (Recent Filing)$1.04B
Total Debt (Recent Filing)$256.20M
Price to Earnings (P/E)36.2
Beta0.42
Next Earnings
Oct 29, 2024EPS Estimate
$1.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.31
Shares Outstanding100,976,249
10 Day Avg. Volume1,019,951
30 Day Avg. Volume925,194
Standard Deviation0.09
R-Squared0.05
Alpha0.00313
Financial Highlights & Ratios
Price to Book (P/B)4.82
Price to Sales (P/S)5.83
Price to Cash Flow (P/CF)47.80
P/FCF Ratio58.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.34
Enterprise Value/Gross Profit6.13
Enterprise Value/Ebitda23.47
Forecast
1Y Price Target
$168.00Price Target Upside40.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
Neurocrine News
Bulls Say, Bears Say
Bulls Say
Market OpportunityCrinecerfont in congenital adrenal hyperplasia is viewed as an attractive commercial opportunity.
Product LaunchThe launch of crinecerfont is a key catalyst, as the company is actively preparing for it.
Stock ValuationThe commercial performance of the Ingrezza franchise contributes significantly to the stock's price objective.
Bears Say
Drug EfficacyThe 20mg once-daily dose did not meet market expectations compared to competitors in development.
Investor ConfidenceIf emraclidine fails, NBIX could be down $5-$10 per share as investors may lose confidence.
Pipeline QualityRenewed questions on pipeline quality following recent '568 data.
---
Ownership Overview
16.03% Insiders
25.66% Mutual Funds
55.27% Other Institutional Investors
3.05% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $103.63 and its highest was $157.98 in the past 12 months.
What is Neurocrine’s market cap?
Currently, no data Available
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is Oct 29, 2024 which is in 40 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on Aug 01, 2024. The company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $1.128 by -$0.498.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is $1.54.
How many shares outstanding does Neurocrine have?
Neurocrine has 100,976,250 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $0.63 in its last earnings report, missing expectations of $1.128. Following the earnings report the stock price went up 8.18%.
Which hedge fund is a major shareholder of Neurocrine?
Among the largest hedge funds holding Neurocrine’s share is Dodge & Cox. It holds Neurocrine’s shares valued at 176M.
---
Neurocrine Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$168.00 (40.18% Upside)
$168.00 (40.18% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 74.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.03%
12-Months-Change
Fundamentals
Return on Equity
15.55%
Trailing 12-Months
Asset Growth
26.48%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.
---
NBIX Company Deck
---
NBIX Earnings Call
Q2 2024
0:00 / 0:00
---
NBIX Stock 12 Month Forecast
Average Price Target
$168.00
▲(40.18% Upside)
Technical Analysis
Best Analysts Covering NBIX
1 Year
1 Year Success Rate
16/23 ratings generated profit
1 Year Average Return
+8.30%
assigned a buy rating 7 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +8.30% per trade.
---